Cranfield collaborator receives multi million dollar financing

November 05, 2004

Cranfield University has been at the forefront of diabetes diagnostics for over twenty years and created the current generation of home blood glucose testing devices used throughout the world. More recently, the University has been working with Pelikan Technologies in Palo Alto, USA to develop the ultimate painless and convenient system and together they have created the first, fully integrated, blood sampling and glucose measurement device - a truly one step procedure.

Now in one of the largest medical device company financings of 2004, Pelikan has announced the closing of a $29.2 million Series D preferred stock financing with several leading international investors. This brings the total financing into the company up to $46.2 million since its founding in 2001.

Pelikan's first product, which is expected to be launched in the spring of 2005, is the Pelikan Sun lancing device. Based on the company's "one-step, one-button" approach, this lancing device is the first fully-automated, electronically-controlled, self-contained system that allows a patient to execute the entire lancing process at the touch of a button in a virtually painless operation. Lancing, an often painful act of piercing the skin in order to obtain a sample of blood for glucose measurement, is required multiple times each day for millions of people with diabetes.

Head of Cranfield University at Silsoe, Professor Tony Turner was intimately involved in the development of this innovative product and said " The device, not only improves the ease of use and convenience for people with diabetes but it also significantly reduces the pain of a procedure that millions of diabetics go through multiple times a day. This is an especially important breakthrough for diabetic children, who often have very sensitive skin."

Proceeds from this financing will be primarily used to support Pelikan's commercialisation of the FDA-cleared Pelikan SunTM lancing device, as well as the continued research and development of the company's fully-integrated glucose-testing and monitoring device. Additionally, the company will dedicate resources to further the research and development of innovative product candidates in the diagnostic point-of-care testing markets.

"We are excited to have achieved this important financial milestone, which will enable Pelikan to broaden the commercialization efforts of the Pelikan Sun product," said Pelikan's President and CEO, Dirk Boecker, M.D., Ph.D. "As important, this new capital will allow us to accelerate the development of our cutting-edge fully-integrated glucose-testing and monitoring device, positioning Pelikan to launch the system in 2007."
-end-


Cranfield University

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.